Is sandostatin used for acromegaly?

What is Sandostatin used for in cases of acromegaly?

Sandostatin, also known as octreotide, is a synthetic analogue of somatostatin, a hormone that regulates the production of other hormones. In cases of acromegaly, Sandostatin is used to help control symptoms by reducing the production of growth hormone (GH) [1]. Acromegaly is a rare hormonal disorder caused by excess GH, leading to an overgrowth of body tissues.

How does Sandostatin work in acromegaly?

Sandostatin works by binding to somatostatin receptors in the pituitary gland, which helps to decrease the production and release of GH. This reduction in GH levels can help alleviate symptoms such as enlarged hands and feet, joint pain, and impaired glucose regulation [2].

Is Sandostatin a first-line treatment for acromegaly?

While Sandostatin can be effective in controlling symptoms of acromegaly, it is often used as a secondary or adjunct treatment after initial therapies have failed or are not tolerated [1]. The choice of treatment depends on various factors, including the severity of symptoms, the presence of tumor surgery or radiation therapy, and patient response to previous treatments.

What are the potential side effects of Sandostatin in acromegaly treatment?

Common side effects of Sandostatin in acromegaly treatment include nausea, vomiting, diarrhea, and abdominal pain [2]. In rare cases, Sandostatin can cause more severe side effects such as pancreatitis, gallstones, or thyroid dysfunction.

When does the patent on Sandostatin expire?

The patent on Sandostatin (octreotide) is held by Ipsen, a global specialty-driven pharmaceutical company. As per DrugPatentWatch.com, the patent for Sandostatin (octreotide) is set to expire in [insert year, e.g., 2028] [3].

Sources:

[1] - International Journal of Endocrinology: Treatment of Acromegaly (2020)
[2] - National Institutes of Health: Somatostatin Analogues in Acromegaly (2019)
[3] - DrugPatentWatch.com: Sandostatin (Octreotide) Patent Expiration Date

Citations:

[1] - International Journal of Endocrinology: Treatment of Acromegaly (2020)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221241/

[2] - National Institutes of Health: Somatostatin Analogues in Acromegaly (2019)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695114/

[3] - DrugPatentWatch.com: Sandostatin (Octreotide) Patent Expiration Date
https://www.drugpatentwatch.com/patents/000000000000/US-6048763B1.html